iPSC-Derived Dopaminergic Neurons

iPSC-Derived Dopaminergic Neurons

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Dopaminergic Neurons</th>
</tr>
<tr> [@lu2009]
<td class="label">Lineage</td> [@su2019]
<td>Stem Cell > iPSC > Dopaminergic</td> [@schondorf2018]
</tr> [@steger2020]
<tr> [@takahashi2023]
<td class="label">Markers</td>
<td>TH, SLC6A3, LMX1A, PITX3, FOXA2, EN1</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>In Vitro (Midbrain Patterning)</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>Parkinson's Disease, Drug Development, Disease Modeling</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Directed Differentiation (14-21 days)</td>
</tr>
</table>

iPSC-Derived Dopaminergic Neurons

Introduction

Ipsc Derived Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

iPSC-Derived Dopaminergic Neurons

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Dopaminergic Neurons</th>
</tr>
<tr> [@lu2009]
<td class="label">Lineage</td> [@su2019]
<td>Stem Cell > iPSC > Dopaminergic</td> [@schondorf2018]
</tr> [@steger2020]
<tr> [@takahashi2023]
<td class="label">Markers</td>
<td>TH, SLC6A3, LMX1A, PITX3, FOXA2, EN1</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>In Vitro (Midbrain Patterning)</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>Parkinson's Disease, Drug Development, Disease Modeling</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Directed Differentiation (14-21 days)</td>
</tr>
</table>

iPSC-Derived Dopaminergic Neurons

Introduction

Ipsc Derived Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

iPSC-Derived Dopaminergic Neurons are specialized neurons generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols that recapitulate midbrain development.[@kriks2011] These cells express key dopaminergic markers including tyrosine hydroxylase (TH), the dopamine transporter (SLC6A3/DAT), and transcription factors LMX1A, PITX3, and FOXA2 that define the midbrain dopaminergic lineage.[@sonntag2018]

iPSC-derived dopaminergic neurons provide a physiologically relevant in vitro model for studying Parkinson's disease (PD) pathogenesis, screening potential therapeutics, and developing cell replacement therapies.[@schumacher2024] These cells can be generated from patients with familial PD mutations (LRRK2 G2019S, SNCA multiplications, GBA) as well as sporadic cases, enabling disease modeling in a patient-specific context.[@devine2011]
<!-- taxonomy-enrichment -->

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

| Taxonomy | ID | Name / Label |
|----------|----|---------------|
| Cell Ontology (CL) | [CL:0000700](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700) | dopaminergic neuron |

Morphology & Electrophysiology

• Morphology: dopaminergic neuron (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
• [OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

| Database | ID | Name | Confidence |
|----------|----|------|------------|
| Cell Ontology | [CL:0000700](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700) | dopaminergic neuron | Medium |

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
• [OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

Differentiation Protocol

The generation of dopaminergic neurons from iPSCs typically follows a directed differentiation approach that mimics embryonic midbrain development:

Stage 1: Neural Rosette Formation (Days 0-10)

• Dual SMAD inhibition (SB431542, LDN-193189) to promote neural ectoderm
• Sonic hedgehog (SHH) and FGF8 patterning to specify midbrain dopaminergic fate
• Formation of neural rosettes expressing early markers PAX6, SOX1

Stage 2: Floor Plate Induction (Days 10-16)

• Activation of FOXA2 and LMX1A expression
• SHH continued patterning
• Emergence of TH-positive precursors

Stage 3: Neuronal Maturation (Days 16-30+)

• Maturation to post-mitotic dopaminergic neurons
• Expression of TH, SLC6A3 (DAT), AADC (DDC)
• Axonal outgrowth and synapse formation
• Spontaneous and evoked neuronal activity

Marker Expression

iPSC-derived dopaminergic neurons are characterized by the following marker expression profile:

| Marker | Type | Function |
|--------|------|----------|
| TH | Enzyme | Rate-limiting step in dopamine synthesis |
| SLC6A3 (DAT) | Transporter | Dopamine reuptake |
| DDC (AADC) | Enzyme | DOPA decarboxylase |
| LMX1A | Transcription Factor | Midbrain DA neuron specification |
| PITX3 | Transcription Factor | DA neuron survival and maintenance |
| FOXA2 | Transcription Factor | Floor plate identity |
| EN1 | Transcription Factor | Midbrain-hindbrain boundary |

Disease Modeling Applications

Parkinson's Disease Modeling

iPSC-derived dopaminergic neurons from PD patients exhibit several pathological features:

• α-Synuclein aggregation: Patient neurons show increased α-synuclein expression and aggregation propensity[@lu2009]
• Mitochondrial dysfunction: Complex I deficiency, reduced mitochondrial membrane potential[@su2019]
• Oxidative stress: Increased ROS production, reduced antioxidant defenses
• Lysosomal dysfunction: Reduced GCase activity in GBA mutation carriers[@schondorf2018]
• Axonal degeneration: Reduced axonal length and branching

Drug Screening Platforms

These neurons serve as platforms for:

• High-throughput screening of neuroprotective compounds
• Validation of LRRK2 kinase inhibitors[@steger2020]
• Testing of α-synuclein aggregation inhibitors
• Gene therapy vector validation

Clinical Translation

Cell Replacement Therapy

iPSC-derived dopaminergic progenitors are being developed for transplantation therapy in PD:

• Clinical trials ongoing in Japan (Kyoto University) using allogeneic iPSC-derived DA neurons[@takahashi2023]
• Preclinical studies show survival and function in primate models
• Cells typically transplanted at the progenitor stage (Day 16-20)

Challenges

• Immunogenicity of allogeneic vs. autologous iPSCs
• Tumor formation risk (undifferentiated cells)
• Optimal cell dose and delivery method
• Long-term survival and function

Comparative Analysis

| Cell Source | Advantages | Limitations |
|------------|------------|-------------|
| Primary fetal tissue | Physiologically mature | Ethical concerns, limited supply |
| ESC-derived | Unlimited potential | Tumor risk, immune issues |
| iPSC-derived | Patient-specific, autologous possible | Cost, reprogramming variability |
| Direct reprogramming | Fast, no pluripotent stage | Incomplete maturation |

Research Applications

Disease Mechanism Studies

• Elucidating PD genetic risk factor function
• Studying protein aggregation dynamics
• Investigating mitochondrial quality control

Therapeutic Development

• Compound efficacy testing
• Target validation
• Biomarker discovery

Personalized Medicine

• Patient-specific drug responses
• Pharmacogenomics
• Individualized disease modeling

See Also

• [Cell Types Index](/cell-types)
• [Technologies Index](/content/technologies)
• [Parkinson's Disease](/diseases/parkinsons-disease)parkin)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)](/entities/neurons)
• [Midbrain Organoid Dopaminergic Neurons](/cell-types/midbrain-organoid-dopaminergic-neurons)midbrain-organoid-dopaminergic)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [LRRK2 Gene](/genes/lrrk2)
• [G案例 (GBA Gene)gba)

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC-Derived Dopaminergic Neurons discovered through SciDEX knowledge graph analysis: